CDKN2A and osteosarcoma: Our study demonstrates that 20–23% of primary osteosarcoma biopsies showed intact Rb, but defective p16 INK4A or overexpression of CDK4 and/or CDK6, indicating potential benefit from CDK4/CDK6 inhibition in almost one quarter of osteosarcoma patients.